Role of Progesterone Membrane Receptors in Preeclampsia
Official title: Investigation of Progesterone Membrane Receptor Expression in Placental Tissue of Women With Preeclampsia and Their Potential Role in the Pathogenesis of Preeclampsia
Run by Samsun University · NCT07745036 · Data updated 2026-11-12
This study looks at whether the levels of progesterone membrane receptors in the placenta differ between women with preeclampsia and healthy pregnant women to understand the condition better.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 45 Years |
| Sex | Women only |
| Enrollment | 90 (estimated) |
| Sponsor | Samsun University Academic / other |
| Locations | 1 site (Samsun) |
| Status | Recruiting |
| Started | September 1, 2025 |
| Main results expected | January 1, 2027 |
| Study ends | January 15, 2027 |
| Registry record updated | August 4, 2026 |
| Trial ID | NCT07745036 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Women aged 18-45 with singleton pregnancies; those diagnosed with preeclampsia or healthy normotensive pregnancies delivering at the study center.
✕Probably not a fit
Patients whose placentas show no distinct differences in receptor expression between groups may not gain direct benefit; results are research-focused.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study compares placental expression of PGRMC1, PGRMC2, and PAQR receptors in women with preeclampsia versus healthy controls. Placental tissue collected after delivery will be analyzed for protein and mRNA levels using immunohistochemistry and gene expression methods. The goal is to uncover molecular differences that may illuminate pathways involved in placental development and inflammatory regulation related to preeclampsia. Findings could point to potential biomarkers or targets for therapy, advancing understanding of disease mechanisms. No interventions are tested in participants; analyses are performed on collected tissues at delivery.
Why it matters
Potential benefit: Understanding receptor expression could lead to biomarkers or targets that help predict risk or guide future therapies for preeclampsia.
How similar studies have gone: Previous work has linked progesterone signaling and placental function to pregnancy outcomes; this study extends those findings to receptor-level expression in preeclampsia.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Preeclampsia Group Women aged 18-45 years Singleton pregnancy Diagnosis of preeclampsia according to ACOG criteria Delivery at the study center Written informed consent Control Group Women aged 18-45 years Singleton pregnancy Normotensive healthy pregnancy Delivery at the study center Written informed consent Exclusion Criteria: Age \<18 or \>45 years Multiple gestation Fetal structural or chromosomal anomalies Chronic hypertension Pre-existing diabetes mellitus Autoimmune diseases Renal disease Other major systemic disorders \-
Where it's running
-
Samsun University Faculty of Medicine Samsun Training and Research Hospital
Samsun, Turkey (Türkiye) Recruiting
Study contacts
- Study coordinator: Canan Soyer Çalışkan, MD, Associate Professor
- Email: canan.caliskan@samsun.edu.tr
- Phone: + 90 532 203 55 38
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Predicting Adverse Pregnancy Outcomes in Uganda through Partnerships and Innovation
This study tests whether everyday health data, ultrasound, and blood samples from first-time pregnant women in Uganda can help predict problems like preeclampsia, fetal growth restriction, and preterm birth.
-
Internal jugular vein collapsibility to gauge volume status in preeclampsia vs. normal pregnancy
This study tests whether ultrasound of the internal jugular vein can show differences in fluid status between preeclamptic pregnant people and those with normal blood pressure during planned cesarean delivery.
-
Higher vs lower daily aspirin in high-risk pregnant people
This study tests whether taking 150 mg of aspirin daily is more effective than 75 mg daily in preventing preeclampsia among pregnant people at high risk.
-
Community health worker support to lower blood pressure after pregnancy with high blood pressure
Postpartum patients with high blood pressure after pregnancy will try a program where a trained community health worker helps them monitor blood pressure and manage care for 6 months to see if it lowers blood pressure compared with usual care.
-
Endothelial Biomarkers in Pregnancy: Endothelial Extracellular Vesicles and Hypertensive Disorders
This study tests whether endothelial extracellular vesicles in the blood differ between normotensive pregnant women and those with hypertensive disorders of pregnancy.
-
Antidepressant Therapy for Blood Vessel Health After Preeclampsia
This study tests whether an antidepressant can improve blood vessel health in women who had preeclampsia and may have depression.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.